- JP-listed companies
- WAKAMOTO PHARMACEUTICAL CO.,LTD.
- Income statement
WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) Income statement
Market cap
¥11.8B
P/E ratio
51.4x
Wakamoto Pharmaceutical manufactures branded drugs, generic medicines, and health products like Koryoku Wakamoto for healthcare providers and consumers in Japan and internationally.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 9,532 | 10,047 | 10,448 | 10,736 | 11,183 | 10,830 | 10,901 | 10,740 | 10,917 | 8,896 | 8,383 | 8,660 | 7,738 | 7,789 | 9,907 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 4,775 | 4,916 | 4,974 | 4,816 | 4,623 | 4,724 | 4,407 | 4,027 | 4,552 | 4,139 | 4,167 | 5,176 |
| Gross profit | - | - | - | 5,961 | 6,267 | 5,856 | 6,085 | 6,117 | 6,193 | 4,489 | 4,356 | 4,108 | 3,600 | 3,622 | 4,730 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 5,756 | 6,195 | 5,772 | 6,158 | 6,510 | 7,190 | 5,243 | 4,369 | 3,967 | 3,795 | 4,080 | 4,475 |
| Operating income | - | - | - | 203 | 83 | 87 | -73 | -391 | -996 | -755 | -13 | 141 | -196 | -458 | 256 |
| Income before tax | -248 | 180 | 377 | 234 | 125 | 103 | -80 | -409 | -911 | -605 | 72 | 243 | -162 | -409 | 256 |
| Pretax margin (%) | -2.6 | 1.8 | 3.6 | 2.2 | 1.1 | 1 | -0.7 | -3.8 | -8.3 | -6.8 | 0.9 | 2.8 | -2.1 | -5.3 | 2.6 |
| Provision for income taxes | - | - | - | 148 | 106 | 75 | 48 | -49 | 745 | -101 | 46 | 73 | 50 | -57 | 29 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | -122 | 183 | 845 | 83 | 21 | 95 | 126 | -181 | -1,657 | -602 | 239 | 138 | 109 | 64 | 227 |
| Earnings per share | -3.52 | 5.27 | 24.3 | 2.4 | 0.59 | 2.73 | 3.63 | -5.22 | -47.73 | -17.34 | 6.87 | 3.98 | 3.13 | 1.85 | 6.54 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | 3 | 3 | 3 | 3.5 |